Discontinued — last reported Q1 '18
Kimberly-Clark Allowance for Doubtful Accounts Receivable (Current) decreased by 15.1% to $45.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 15.1%, from $53.00M to $45.00M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows relatively stable performance with a -2.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $55.00M | $64.00M | $78.00M | $53.00M | $45.00M |
| QoQ Change | — | +16.4% | +21.9% | -32.1% | -15.1% |
| YoY Change | — | +16.4% | +21.9% | -32.1% | -15.1% |